Tiziana Life Sciences doses first patient in Phase 2a trial of Foralumab for rare disease

Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce that the first participant has been enrolled and dosed in the company’s Phase 2a clinical trial of intranasal foralumab for patients with Multiple System Atrophy at Brigham and Women’s Hospital in Boston, Massachusetts. Elrifi explained that the six-month open-label study will evaluate whether foralumab can reduce harmful neuroinflammation by activating regulatory T cells through a novel intranasal, non-systemic delivery method. Participants will receive treatment across eight dosing cycles, with the goal of assessing whether the therapy can slow disease progression and improve quality of life. MSA is a rare, rapidly progressing neurodegenerative disorder that impairs movement, balance, and autonomic function. With an estimated 15,000–50,000 cases in the United States and no FDA-approved therapies to alter disease course, there is an urgent need for innovative treatments. The trial is part of Tiziana’s broader clinical strategy exploring foralumab in neuroinflammatory and neurodegenerative diseases, where earlier studies have shown promising signs of stabilizing or improving patient function in conditions like multiple sclerosis. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #AlzheimersResearch #Neuroinflammation #BiotechNews #PETscan #ClinicalTrials #AlzheimersTreatment #PharmaUpdates #HealthcareInnovation